JP2023518443A5 - - Google Patents
Info
- Publication number
- JP2023518443A5 JP2023518443A5 JP2022556175A JP2022556175A JP2023518443A5 JP 2023518443 A5 JP2023518443 A5 JP 2023518443A5 JP 2022556175 A JP2022556175 A JP 2022556175A JP 2022556175 A JP2022556175 A JP 2022556175A JP 2023518443 A5 JP2023518443 A5 JP 2023518443A5
- Authority
- JP
- Japan
- Prior art keywords
- mutant protein
- sequence
- protein according
- mutant
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010196689.5 | 2020-03-19 | ||
| CN202010196689 | 2020-03-19 | ||
| PCT/CN2021/081841 WO2021185362A1 (zh) | 2020-03-19 | 2021-03-19 | 白介素2突变体及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023518443A JP2023518443A (ja) | 2023-05-01 |
| JP2023518443A5 true JP2023518443A5 (https=) | 2024-04-02 |
Family
ID=77768025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022556175A Pending JP2023518443A (ja) | 2020-03-19 | 2021-03-19 | インターロイキン２変異体およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230174604A1 (https=) |
| EP (1) | EP4122951A4 (https=) |
| JP (1) | JP2023518443A (https=) |
| KR (1) | KR20220155317A (https=) |
| CN (2) | CN115315437B (https=) |
| AU (1) | AU2021237518B2 (https=) |
| CA (1) | CA3175728A1 (https=) |
| TW (1) | TWI834031B (https=) |
| WO (1) | WO2021185362A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3854805A4 (en) | 2018-09-21 | 2022-08-24 | Innovent Biologics (Suzhou) Co., Ltd. | NOVEL INTERLEUKIN 2 AND ITS USE |
| CA3098930A1 (en) | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
| JP2023518434A (ja) * | 2020-03-19 | 2023-05-01 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | インターロイキン２変異体およびその使用 |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4406965A4 (en) * | 2021-09-22 | 2025-12-17 | Fortvita Biologics Singapore Pte Ltd | INTERLEUKIN-2 MUTANT AND FUSION PROTEIN OF WHICH |
| CN118510795A (zh) * | 2022-01-07 | 2024-08-16 | 苏州克睿基因生物科技有限公司 | 新型白介素-2多肽 |
| EP4499846A1 (en) | 2022-03-25 | 2025-02-05 | Universität Zürich | Adenoviral mediated targeting of activated immune cells |
| CN114853909A (zh) * | 2022-05-13 | 2022-08-05 | 南京吉盛澳玛生物医药有限公司 | 新型IL-2与INFα和Fc融合蛋白的设计、制备及用途 |
| CN116041539B (zh) * | 2022-10-31 | 2023-07-21 | 山东博安生物技术股份有限公司 | Il-2突变体免疫缀合物 |
| KR102629162B1 (ko) | 2022-11-04 | 2024-01-29 | 한국기초과학지원연구원 | 바이오의약품 품질관리를 위한 잔류 숙주세포 단백질 정량 분석 방법 및 시스템 |
| CN120500496A (zh) * | 2023-01-04 | 2025-08-15 | 北京晶泰科技有限公司 | 白细胞介素-2变体及其应用 |
| CN118680877A (zh) * | 2023-03-21 | 2024-09-24 | 信达生物制药(苏州)有限公司 | 抗pd-1与突变il-2免疫缀合物制剂 |
| WO2025010341A2 (en) * | 2023-07-05 | 2025-01-09 | The Trustees Of Dartmouth College | Cytokine hybrid proteins and methods related thereto |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| NZ234674A (en) * | 1989-08-02 | 1992-02-25 | Seragen Inc | Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US6960652B2 (en) * | 1999-03-30 | 2005-11-01 | Board Of Regents, The University Of Texas System | Compositions and methods for modifying toxic effects of proteinaceous compounds |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| US20060234205A1 (en) * | 2004-03-05 | 2006-10-19 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CN102101885B (zh) * | 2010-09-01 | 2013-06-05 | 南京发士达生物科技有限公司 | 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途 |
| SG192673A1 (en) * | 2011-02-10 | 2013-09-30 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
| WO2012119093A1 (en) * | 2011-03-03 | 2012-09-07 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| US9580486B2 (en) * | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| CN104231068A (zh) * | 2014-01-27 | 2014-12-24 | 苏州发士达生物科技有限公司 | 人白细胞介素ii突变体及其应用 |
| PT3102595T (pt) * | 2014-02-06 | 2019-01-11 | Hoffmann La Roche | Proteínas de fusão de interleucina-2 e suas utilizações |
| WO2015164815A1 (en) * | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| MX2021000801A (es) * | 2018-07-24 | 2021-04-12 | BioNTech SE | Agonistas de il2. |
| CA3098930A1 (en) * | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
| EP3854805A4 (en) * | 2018-09-21 | 2022-08-24 | Innovent Biologics (Suzhou) Co., Ltd. | NOVEL INTERLEUKIN 2 AND ITS USE |
| JP2023518434A (ja) * | 2020-03-19 | 2023-05-01 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | インターロイキン２変異体およびその使用 |
| EP4273161A4 (en) * | 2020-12-31 | 2025-04-02 | Innovent Biologics (Suzhou) Co., Ltd. | Protein with heterodimeric antibody FC and manufacturing method therefor |
-
2021
- 2021-03-19 AU AU2021237518A patent/AU2021237518B2/en active Active
- 2021-03-19 CN CN202180021829.8A patent/CN115315437B/zh active Active
- 2021-03-19 US US17/911,922 patent/US20230174604A1/en active Pending
- 2021-03-19 EP EP21770699.3A patent/EP4122951A4/en active Pending
- 2021-03-19 JP JP2022556175A patent/JP2023518443A/ja active Pending
- 2021-03-19 KR KR1020227034881A patent/KR20220155317A/ko active Pending
- 2021-03-19 CN CN202511440514.3A patent/CN121574230A/zh active Pending
- 2021-03-19 WO PCT/CN2021/081841 patent/WO2021185362A1/zh not_active Ceased
- 2021-03-19 TW TW110110009A patent/TWI834031B/zh active
- 2021-03-19 CA CA3175728A patent/CA3175728A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023518443A5 (https=) | ||
| US11919931B2 (en) | Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3) | |
| TWI790573B (zh) | 白介素２突變體及其用途 | |
| JP7765181B2 (ja) | 改変されたｉｌ－２ ｆｃ融合タンパク質 | |
| JP2023518434A5 (https=) | ||
| AU2017201056B2 (en) | Multimeric il-15 soluble fusion molecules and methods of making and using same | |
| CN112105634A (zh) | 新型白介素2及其用途 | |
| JP5077924B2 (ja) | 分泌された三量体受容体類似体及び生物学的活性融合タンパク質を製造するための方法及び組成物 | |
| KR20190129896A (ko) | Tgf-β-수용체 엑토도메인 융합 분자 및 그의 용도 | |
| JP2015531751A (ja) | 選択的対である軽鎖および重鎖を含む免疫グロブリン構築物 | |
| KR20170017846A (ko) | Ｓｉｒｐ-알파 변이체 구성체 및 이의 용도 | |
| JPH09508009A (ja) | Ｆａｓ抗原を結合するリガンド | |
| WO2000017350A1 (fr) | Sequence codante pour un nouveau facteur de differenciation de la croissance d'origine humaine et polypeptide code par cette sequence d'adn, et methode de production correspondante | |
| CN111892661A (zh) | 一种嵌合抗原受体及其在制备治疗肿瘤的产品中的应用 | |
| WO2022226054A2 (en) | Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof | |
| JP2005535353A (ja) | Ｃ４ｂｐスカフォールドを使用した、多量体融合タンパク質の産生 | |
| US20040009950A1 (en) | Secreted human proteins | |
| CN113912735B (zh) | 多肽二聚体及其用途 | |
| US7485621B2 (en) | Tumor tag and the use thereof | |
| CN112480237B (zh) | 一种融合蛋白及其制备方法和应用 | |
| JPH0380096A (ja) | モチリン様ポリペプチドの製法並びにそのための組換えｄｎａ及び発現用プラスミド | |
| US7462704B2 (en) | Tumor marker and its use | |
| WO2022007885A1 (zh) | 融合多肽和多肽二聚体及其用途 | |
| WO2026036390A1 (zh) | 白介素12突变体及其用途 | |
| KR20250047619A (ko) | Tnfr2 결합 에이전트를 인코딩하는 핵산을 포함하는 유전자 변형된 세포 및 이의 용도 |